Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.58 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 10/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | LDHA | P00338 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29730411 | 0.90 | CNR1 (0.67) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL23168056 | 0.90 | CNR1 (0.67) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL23167667 | 0.89 | CNR1 (0.56) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL23167748 | 0.88 | CNR1 (0.68) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL23166670 | 0.88 | CNR1 (0.55) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL29730325 | 0.88 | CNR1 (0.55) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL29730292 | 0.87 | CNR1 (0.54) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL29730256 | 0.87 | CNR1 (0.65) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL23166712 | 0.87 | CNR1 (0.54) | CNR1DAGLANAAACNR2TRPV1 | |
| SCHEMBL20987927 | 0.87 | DAGLA (0.66) | CNR1DAGLANAAACNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325709-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2025-06-10 | — | — | US | claimed |
| US-20220348586-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2022-11-03 | — | — | US | claimed |
| EP-4037676-A1 | CANNABINOID DERIVATIVES | Canopy Growth Corporation (CA) | 2022-08-10 | — | — | EP | claimed |
| WO-2021062559-A1 | CANNABINOID DERIVATIVES | CANOPY GROWTH CORPORATION (CA) | 2021-04-08 | — | — | WO | claimed |
| US-12325709-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2025-06-10 | — | — | US | disclosed |
| US-20220348586-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2022-11-03 | — | — | US | disclosed |
| EP-4037676-A1 | CANNABINOID DERIVATIVES | Canopy Growth Corporation (CA) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021062559-A1 | CANNABINOID DERIVATIVES | CANOPY GROWTH CORPORATION (CA) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325709-B2 | Cannabinoid derivatives | CNR1, CNR2, GPR68 | CNR1 1/4885DAGLA 596/4885NAAA 901/4885 |
| US-20220348586-A1 | CANNABINOID DERIVATIVES | CNR1, CNR2, GPR68 | CNR1 1/4885DAGLA 596/4885NAAA 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.